Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Pain and Headache Reports
Published in: Current Pain and Headache Reports 2/2010

01-04-2010

The Effect of Morphine on Glial Cells as a Potential Therapeutic Target for Pharmacological Development of Analgesic Drugs

Authors: Haroon Hameed, Mariam Hameed, Paul J. Christo

Published in: Current Pain and Headache Reports | Issue 2/2010

Login to get access

Abstract

Opioids have played a critical role in achieving pain relief in both modern and ancient medicine. Yet, their clinical use can be limited secondary to unwanted side effects such as tolerance, dependence, reward, and behavioral changes. Identification of glial-mediated mechanisms inducing opioid side effects include cytokine receptors, κ-opioid receptors, N-methyl-D-aspartate receptors, and the recently elucidated Toll-like receptors. Newer agents targeting these receptors such as AV411, MK-801, AV333, and SLC022, and older agents used outside the United States or for other disease conditions, such as minocycline, pentoxifylline, and UV50488H, all show varied but promising profiles for providing significant relief from opioid side effects, while simultaneously potentiating opioid analgesia.
Literature
1.
•• Hutchinson MR, Bland ST, Johnson KW, et al.: Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. ScientificWorldJournal 2007, 7:98–111. This article discusses TLRs and modifying agents and their relevance to the future of the management of pain. It also includes detailed information related to the research regarding naloxone in the management of opioid side effects.
2.
Coyle DE: Partial peripheral nerve injury leads to activation of astroglia and microglia which parallels the development of allodynic behavior. Glia 1998, 23:75–83.CrossRefPubMed
3.
McMahon SB (2002) Neuropathic pain mechanisms. In: Giamberardino MA (ed) Pain 2002—an updated review. Seattle: IASP Press, 155–164.
4.
Nakajima K, Kohsaka S: Functional roles of microglia in the brain. Neurosci Res 1993, 17:187–203.CrossRefPubMed
5.
Milligan ED, Watkins LR: Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 2009, 10:23–36.CrossRefPubMed
6.
Halassa MM, Fellin T, Haydon PG: The tripartite synapse: roles for gliotransmission in health and disease. Trends Mol Med 2007, 13:54–63.CrossRefPubMed
7.
Pocock JM, Kettenmann H: Neurotransmitter receptors on microglia. Trends Neurosci 2007, 30:527–535.CrossRefPubMed
8.
Cao H, Zhang YQ: Spinal glial activation contributes to pathological pain states. Neurosci Biobehav Rev 2008, 32:972–983.CrossRefPubMed
9.
Ji RR, Gereau RW 4th, Malcangio M, Strichartz GR: MAP kinase and pain. Brain Res Rev 2009, 60:135–148.CrossRefPubMed
10.
Watkins LR, Maier SF: The pain of being sick: implications of immune-to-brain communication for understanding pain. Annu Rev Psychol 2000, 51:29–57.CrossRefPubMed
11.
Minghetti L, Levi G: Microglia as effector cells in brain damage and repair: focus on prostanoids and nitric oxide. Prog Neurobiol 1998, 54:99–125.CrossRefPubMed
12.
Hutchinson MR, Coats BD, Lewis SS, et al.: Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia. Brain Behav Immun 2008, 22:1178–1189.CrossRefPubMed
13.
Malcangio M, Bowery NG, Flower RJ, Perretti M: Effect of interleukin-1 on the release of substance P from rat isolated spinal cord. Eur J Pharmacol 1996, 299:113–118.CrossRefPubMed
14.
•• Mika J: Modulation of microglia can attenuate neuropathic pain symptoms and enhance morphine effectiveness. Pharmacol Rep 2008, 60:297–307. This review discusses the roles of various cytokine-related cascades in addition to other TLR-related mechanisms in the generation of nonopioid receptor-mediated opioid effects and the agents that may be employed to modify them.
15.
Obreja O, Rathee PK, Lips KS, et al.: IL-1 potentiates heat-activated currents in rat sensory neurons: involvement of IL-1RI, tyrosine kinase, and protein kinase C. FASEB J 2002, 16:1497–1503.CrossRefPubMed
16.
Flatters SJ, Fox AJ, Dickenson AH: Spinal interleukin-6 (IL-6) inhibits nociceptive transmission following neuropathy. Brain Res 2003, 984:54–62.CrossRefPubMed
17.
Moore KW, O’Garra A, de Waal Malefyt R, et al.: Interleukin-10. Annu Rev Immunol 1993, 11:165–190CrossRefPubMed
18.
19.
Sawada M, Suzumura A, Hosoya H, et al.: Interleukin-10 inhibits both production of cytokines and expression of cytokine receptors in microglia. J Neurochem 1999, 72:1466–1471.CrossRefPubMed
20.
Huber TS, Gaines GC, Welborn MB 3rd, et al.: Anticytokine therapies for acute inflammation and the systemic inflammatory response syndrome: IL-10 and ischemia/reperfusion injury as a new paradigm. Shock 2000, 13:425–434.PubMed
21.
Merrill JE, Benveniste EN: Cytokines in inflammatory brain lesions: helpful and harmful. Trends Neurosci 1996, 19:331–338.CrossRefPubMed
22.
Fontaine V, Mohand-Said S, Hanoteau N, et al.: Neurodegenerative and neuroprotective effects of tumor necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. J Neurosci 2002, 22:RC216.PubMed
23.
Tanga FY, Nutile-McMenemy N, Deleo JA: The CNS role of Toll-like receptor 4 in innate neuroimmunity and painful neuropathy. Proc Natl Acad Sci U S A 2005, 102: 5856–5861.CrossRefPubMed
24.
Kim D, Kim MA, Cho IH, et al.: A critical role of toll-like receptor 2 in nerve injury-induced spinal cord glial cell activation and pain hypersensitivity. J Biol Chem 2007, 282:14975–14983.CrossRefPubMed
25.
Muzio M, Mantovani A: Toll-like receptors (TLRs) signalling and expression pattern. J Endotoxin Res 2001, 7:297–300.PubMed
26.
•• Guo LH, Schluesener HJ: The innate immunity of the central nervous system in chronic pain: the role of Toll-like receptors. Cell Mol Life Sci 2007, 64:1128–1136. This article offers a detailed discussion on TLRs and their role in the development of various types of pain.
27.
28.
•• Watkins LR, Hutchinson MR, Rice KC, Maier SF: The “toll” of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci 2009, 30:581–591. This is a very recent review of TLR receptors and the current foci of interest in the management of dependence, reward, and other opioid-related side effects.
29.
Kakimura J, Kitamura Y, Takata K, et al.: Microglial activation and amyloid-beta clearance induced by exogenous heat-shock proteins. FASEB J 2002, 16:601–603.PubMed
30.
Tsuda M, Shigemoto-Mogami Y, Koizumi S, et al.: P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature 2003, 424:778–783.CrossRefPubMed
31.
Horvath RJ, DeLeo JA: Morphine enhances microglial migration through modulation of P2X4 receptor signaling. J Neurosci 2009, 29:998–1005.CrossRefPubMed
32.
McMahon SB, Cafferty WB, Marchand F: Immune and glial cell factors as pain mediators and modulators. Exp Neurol 2005, 192:444–462.CrossRefPubMed
33.
•• Hutchinson MR, Zhang Y, Shridhar M, et al.: Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun 2010, 24:83–95. This paper summarizes recent information regarding the highly central role of TLR-4 receptors with implications to the current developments in the opioid-related tolerance and dependence modifying agents.
34.
Juni A, Klein G, Pintar JE, Kest B: Nociception increases during opioid infusion in opioid receptor triple knock-out mice. Neuroscience 2007, 147:439–444.CrossRefPubMed
35.
Shu H, Hayashida M, Huang W, et al.: The comparison of effects of processed Aconiti tuber, U50488H and MK-801 on the antinociceptive tolerance to morphine. J Ethnopharmacol 2008, 117:158–165.CrossRefPubMed
36.
•• Ueda H, Ueda M: Mechanisms underlying morphine analgesic tolerance and dependence. Front Biosci 2009, 14:5260–5272. This is a highly detailed review of the protein pathways responsible for the development of opioid tolerance and dependence. This review includes discussions on protein kinase receptor phosphorylations, NMDA receptors, neurotrophins, and various other neuropeptides.
37.
Xu M, Bruchas MR, Ippolito DL, et al.: Sciatic nerve ligation-induced proliferation of spinal cord astrocytes is mediated by kappa opioid activation of p38 mitogen-activated protein kinase. J Neurosci 2007, 27:2570–2581.CrossRefPubMed
38.
• Ledeboer A, Hutchinson MR, Watkins LR, Johnson KW: Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opin Investig Drugs 2007, 16:935–950. This review details the effectiveness of ibudilast in the management of opioid tolerance and reward.
39.
Kishi Y, Ohta S, Kasuya N, et al.: Ibudilast: a non-selective PDE inhibitor with multiple actions on blood cells and the vascular wall. Cardiovasc Drug Rev 2001, 19:215–225.PubMedCrossRef
40.
Fujimoto T, Sakoda S, Fujimura H, Yanagihara T: Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats. J Neuroimmunol 1999, 95:35–42.CrossRefPubMed
41.
Feng J, Misu T, Fujihara K, et al.: Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis. Mult Scler 2004, 10:494–498.CrossRefPubMed
42.
Harris GC, Aston-Jones G: Involvement of D2 dopamine receptors in the nucleus accumbens in the opiate withdrawal syndrome. Nature 1994, 371:155–157.CrossRefPubMed
43.
• Bland ST, Hutchinson MR, Maier SF, et al.: The glial activation inhibitor AV411 reduces morphine-induced nucleus accumbens dopamine release. Brain Behav Immun 2009, 23:492–497. This review discusses the mechanism of action of AV411 and its relationship to TLRs.
44.
Kest B, Mogil JS, Shamgar BE, et al.: The NMDA receptor antagonist MK-801 protects against the development of morphine tolerance after intrathecal administration. Proc West Pharmacol Soc 1993, 36:307–310.PubMed
45.
Guo RX, Zhang M, Liu W, et al.: NMDA receptors are involved in upstream of the spinal JNK activation in morphine antinociceptive tolerance. Neurosci Lett 2009, 467:95–99.CrossRefPubMed
46.
Morgan MM, Bobeck EN, Ingram SL: Glutamate modulation of antinociception, but not tolerance, produced by morphine microinjection into the periaqueductal gray of the rat. Brain Res 2009, 1295:59–66.CrossRefPubMed
47.
Schmidt AP, Tort AB, Silveira PP, et al.: The NMDA antagonist MK-801 induces hyperalgesia and increases CSF excitatory amino acids in rats: reversal by guanosine. Pharmacol Biochem Behav 2009, 91:549–553.CrossRefPubMed
48.
Sweitzer SM, Pahl JL, DeLeo JA: Propentofylline attenuates vincristine-induced peripheral neuropathy in the rat. Neurosci Lett 2006, 400:258–261.CrossRefPubMed
49.
Gwak YS, Crown ED, Unabia GC, Hulsebosch CE: Propentofylline attenuates allodynia, glial activation and modulates GABAergic tone after spinal cord injury in the rat. Pain 2008, 138:410–422.CrossRefPubMed
50.
Narita M, Miyatake M, Narita M, et al.: Direct evidence of astrocytic modulation in the development of rewarding effects induced by drugs of abuse. Neuropsychopharmacology 2006, 31:2476–2488.CrossRefPubMed
51.
Mika J, Wawrzczak-Bargiela A, Osikowicz M, et al.: Attenuation of morphine tolerance by minocycline and pentoxifylline in naive and neuropathic mice. Brain Behav Immun 2009, 23:75–84.CrossRefPubMed
52.
53.
Li WW, Setzu A, Zhao C, Franklin RJ: Minocycline-mediated inhibition of microglia activation impairs oligodendrocyte progenitor cell responses and remyelination in a non-immune model of demyelination. J Neuroimmunol 2005, 158:58–66.CrossRefPubMed
54.
Ledeboer A, Sloane EM, Milligan ED, et al.: Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain 2005, 115:71–83.CrossRefPubMed
55.
Zanjani TM, Sabetkasaei M, Mosaffa N, et al.: Suppression of interleukin-6 by minocycline in a rat model of neuropathic pain. Eur J Pharmacol 2006, 538:66–72.CrossRefPubMed
56.
Piao ZG, Cho IH, Park CK, et al.: Activation of glia and microglial p38 MAPK in medullary dorsal horn contributes to tactile hypersensitivity following trigeminal sensory nerve injury. Pain 2006, 121:219–231.CrossRefPubMed
57.
Cui Y, Liao XX, Liu W, et al.: A novel role of minocycline: attenuating morphine antinociceptive tolerance by inhibition of p38 MAPK in the activated spinal microglia. Brain Behav Immun 2008, 22:114–123.CrossRefPubMed
58.
Wei T, Sabsovich I, Guo TZ, et al.: Pentoxifylline attenuates nociceptive sensitization and cytokine expression in a tibia fracture rat model of complex regional pain syndrome. Eur J Pain 2009, 13:253–262.CrossRefPubMed
59.
Dorazil-Dudzik M, Mika J, Schafer MK, et al.: The effects of local pentoxifylline and propentofylline treatment on formalin-induced pain and tumor necrosis factor-alpha messenger RNA levels in the inflamed tissue of the rat paw. Anesth Analg 2004, 98:1566–1573.CrossRefPubMed
60.
Liu J, Feng X, Yu M, et al.: Pentoxifylline attenuates the development of hyperalgesia in a rat model of neuropathic pain. Neurosci Lett 2007, 412:268–272.CrossRefPubMed
Metadata
Title
The Effect of Morphine on Glial Cells as a Potential Therapeutic Target for Pharmacological Development of Analgesic Drugs
Authors
Haroon Hameed
Mariam Hameed
Paul J. Christo
Publication date
01-04-2010
Publisher
Current Science Inc.
Published in
Current Pain and Headache Reports / Issue 2/2010
Print ISSN: 1531-3433
Electronic ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-010-0093-y

Other articles of this Issue 2/2010

Current Pain and Headache Reports 2/2010 Go to the issue

ReviewPaper

Deep Brain Stimulation in Cluster Headache: Hypothalamus or Midbrain Tegmentum?

ReviewPaper

Resilience: A New Paradigm for Adaptation to Chronic Pain

ReviewPaper

Prolonged Fasting as a Method of Mood Enhancement in Chronic Pain Syndromes: A Review of Clinical Evidence and Mechanisms

ReviewPaper

Intravenous Lidocaine and Mexiletine in the Management of Trigeminal Autonomic Cephalalgias

ReviewPaper

Chronic Pain in Torture Victims

ReviewPaper

Genetics of Cluster Headache